THZ531 Induces a State of BRCAness in Multiple Myeloma Cells : Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
Multiple myeloma (MM) is a hematological disease marked by abnormal growth of B cells in bone marrow. Inherent chromosomal instability and DNA damage are major hallmarks of MM, which implicates an aberrant DNA repair mechanism. Studies have implicated a role for CDK12 in the control of expression of DNA damage response genes. In this study, we examined the effect of a small molecule inhibitor of CDK12-THZ531 on MM cells. Treatment of MM cells with THZ531 led to heightened cell death accompanied by an extensive effect on gene expression changes. In particular, we observed downregulation of genes involved in DNA repair pathways. With this insight, we extended our study to identify synthetic lethal mechanisms that could be exploited for the treatment of MM cells. Combination of THZ531 with either DNA-PK inhibitor (KU-0060648) or PARP inhibitor (Olaparib) led to synergistic cell death. In addition, combination treatment of THZ531 with Olaparib significantly reduced tumor burden in animal models. Our findings suggest that using a CDK12 inhibitor in combination with other DNA repair inhibitors may establish an effective therapeutic regimen to benefit myeloma patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 23(2022), 3 vom: 21. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shyamsunder, Pavithra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anilides |
|---|
| Anmerkungen: |
Date Completed 04.03.2022 Date Revised 04.03.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms23031207 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336952317 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336952317 | ||
| 003 | DE-627 | ||
| 005 | 20231225233319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms23031207 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM336952317 | ||
| 035 | |a (NLM)35163134 | ||
| 035 | |a (PII)1207 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shyamsunder, Pavithra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a THZ531 Induces a State of BRCAness in Multiple Myeloma Cells |b Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2022 | ||
| 500 | |a Date Revised 04.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Multiple myeloma (MM) is a hematological disease marked by abnormal growth of B cells in bone marrow. Inherent chromosomal instability and DNA damage are major hallmarks of MM, which implicates an aberrant DNA repair mechanism. Studies have implicated a role for CDK12 in the control of expression of DNA damage response genes. In this study, we examined the effect of a small molecule inhibitor of CDK12-THZ531 on MM cells. Treatment of MM cells with THZ531 led to heightened cell death accompanied by an extensive effect on gene expression changes. In particular, we observed downregulation of genes involved in DNA repair pathways. With this insight, we extended our study to identify synthetic lethal mechanisms that could be exploited for the treatment of MM cells. Combination of THZ531 with either DNA-PK inhibitor (KU-0060648) or PARP inhibitor (Olaparib) led to synergistic cell death. In addition, combination treatment of THZ531 with Olaparib significantly reduced tumor burden in animal models. Our findings suggest that using a CDK12 inhibitor in combination with other DNA repair inhibitors may establish an effective therapeutic regimen to benefit myeloma patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRCAness | |
| 650 | 4 | |a DNA repair | |
| 650 | 4 | |a Olaparib | |
| 650 | 4 | |a THZ531 | |
| 650 | 7 | |a Anilides |2 NLM | |
| 650 | 7 | |a BRCA1 Protein |2 NLM | |
| 650 | 7 | |a BRCA1 protein, human |2 NLM | |
| 650 | 7 | |a BRCA2 Protein |2 NLM | |
| 650 | 7 | |a BRCA2 protein, human |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a THZ531 |2 NLM | |
| 700 | 1 | |a Sridharan, Shree Pooja |e verfasserin |4 aut | |
| 700 | 1 | |a Madan, Vikas |e verfasserin |4 aut | |
| 700 | 1 | |a Dakle, Pushkar |e verfasserin |4 aut | |
| 700 | 1 | |a Zeya, Cao |e verfasserin |4 aut | |
| 700 | 1 | |a Kanojia, Deepika |e verfasserin |4 aut | |
| 700 | 1 | |a Chng, Wee-Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, S Tiong |e verfasserin |4 aut | |
| 700 | 1 | |a Koeffler, H Phillip |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 23(2022), 3 vom: 21. Jan. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:3 |g day:21 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms23031207 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 3 |b 21 |c 01 | ||